Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have also been one of the first companies to test antibody combinations as a possibly improved method of cancer therapy, and as a result have also embarked on the development of bispecific (bifunctional) monoclonal antibodies targeting two distinct antigens on the same cancer cells. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.01 |
| Quarterly EPS Est: | -0.09 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research
